CrossAssetDataThe Company File
···
AQST

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Warren, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $45 million and a loss of $84 million (its filed statements).

Product business Pharmaceutical Preparations Warren, NJ filings since 2007 8 of 9 filed, 1 estimated
Ask the desk about AQST → Compare AQST with GYRE → Price chart on TradingView ↗ Full EDGAR file ↗ Watch AQST →

Sector peers: GYREXLOCTMXGOSS

3.9/10headline grade
vs its business-model standard
3.9/10past 3.9/10present 4.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 3.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.9 out of ten, present 3.9 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 5.0 out of ten. 2 warning events since 2017; the latest 2023-01-03. 50th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.4 out of ten. -5.8% a year over 8 filed years; profitable in 0 of 8. 34th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 3.1 out of ten. CrossAssetData estimate 3.1/10, confidence 35 of 100 (one part). 31st percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 3.1 out of ten. Leverage 121%: owes 121¢ per asset dollar. 31st percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 4.5 out of ten. bottom 45% of 314 in its family; net margin -188.1%. 45th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.6 out of ten. bottom 46% of 315 in its family for leadership; chief executive since 2022. 46th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.6 out of ten. bottom 46% of 272 in its family for room to expand. 46th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.9 out of ten. bottom 49% of 307 in its family for growth drivers. 49th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 1.9 out of ten. bottom 19% of 234 in its family for expectations against reality. 19th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-04 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-11 (on EDGAR). Newest filing: Form SCHEDULE 13G, 2026-10-07. Filings on record since 2007. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Manufacture and Supply Revenue 90%, License and Royalty Revenue 8%, Royalty 2%. By geography: United States 67%, Ex-United States 34%. As tagged in its annual report (Form 10-K, filed 2026-03-04).

Who runs it

Barber, Daniel (President and CEO); Toth, A Ernest Jr (Chief Financial Officer); Jung, Cassie (Chief Operating Officer); Korczynski, Sherry (Chief Commercial Officer); Boyd, Peter E. (Chief People Officer); Zalewski, Thomas A. (Chief Legal Officer); Davis, Matthew W. (Chief Development Officer); Greenhawt, Matthew J. (Chief Medical Officer); Kraus, Carl N (Chief Medical Officer); Cioffi, Melina (SVP, Regulatory Affairs); and 7 more. 17 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.